LINCOLN, Mass., July 10, 2017 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their involvement in the upcoming Antibody Protein Therapeutics Summit on July 11-12, 2017 in Baltimore, MD. Jennifer Park, PhD, Associate Director of Business Development at Applied BioMath, will present a poster entitled "Computational exploration of mechanistic determinants of antibody drug-conjugate pharmacokinetics using quantitative systems pharmacology modeling strategies."
Applied BioMath's poster highlights how their quantitative systems pharmacology (QSP) approach provides biological insights into the impact of drug-to-antibody ratio and the resulting changes in molecular properties on overall pharmacokinetics (PK) and relative payload disposition as observed in preclinical and clinical studies. This approach, based on research led by Anna Katharina Wilkins, PhD, Principal Scientist at Applied BioMath, explores the PK of antibody-drug conjugate (ADC) therapeutics which typically show a discrepancy between the PK of total antibody and that of conjugated antibody, carrying one or more payload molecules. This discrepancy is often attributed to deconjugation, however recent evidence suggests that the underlying mechanisms may be more complex.
"This antibody-drug conjugate study is a great example of how QSP modeling approaches provide insights, some of which are counterintuitive, into complex therapeutic platforms. These insights help our collaborators accelerate the development of potentially best-in-class therapeutics and quickly get drug candidates into the clinic, with higher likelihoods of testing proof of clinical concept, ultimately to help patients."
Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath
Applied BioMath is well versed in the use of QSP modeling approaches for ADC therapeutics. Their inaugural presentation of QSP approaches for ADC research received top honors at World ADC 2016. They also announced a recent ADC collaboration in PRNewswire.com's article entitled "Applied BioMath, LLC announces collaboration with Zymeworks Inc. for Clinical Trial Support in Oncology."
About Applied BioMath
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D. Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward. Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug. We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.
Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.
Press contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com
SOURCE Applied BioMath